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Objective. This study is designed to observe the urinary tumor necrosis factor-like weak inducer of apoptosis (TWEAK) levels
in patients with lupus nephritis (LN) and to identify new biomarker of lupus nephritis activity. Methods.S t u d ys u b j e c t sw e r e4 6
cases of patients with LN (including 34 of active cases) who underwent routine renal biopsy. Activity and chronicity indexes of
LN were assessed using pathological criteria proposed by Hill et al. in 2000. Urinary TWEAK (uTWEAK) level and Monocyte
chemoattractant protein-1 (MCP-1) level were detected by ELISA. Results. Urinary TWEAK level was signiﬁcantly higher in active
LN group than in non-active LN group. Correlation analysis showed that urinary TWEAK levels were signiﬁcantly correlated with
activity index (r = 0.825, P<0.01), glomerular activity index (r = 0.754, P<0.01), and tubulointerstitial qualitative activity
index (r = 0.751, P<0.01), while not signiﬁcant correlated with chronicity Index (P>0.05). The association between urinary
TWEAKlevelsandurinaryMCP-1levelsweresigniﬁcantinactiveLNgroup(r = 0.809,P<0.01)butnotsigniﬁcantinnon-active
LN group (P>0.05). Conclusions. uWEAK levels were correlated with all active indexes of LN, suggesting its potential role as novel
biomarker of active lupus nephritis.
1.Introduction
Systemic lupus erythematosus (SLE) is a chronic autoim-
mune disease characterized by complex clinical manifesta-
tion and chronic inﬂammatory processes involving autoim-
munityagainstmultiplesystemsandmultipleorgans.Kidney
is one of the most commonly aﬀected organs. Lupus nephri-
tis (LN), the appearance of a disservice caused by SLE to
kidney, contributes to high mortality. As active stage and rest
stage alternate iteratively in LN disease process, observation
to SLE activity, especially to the level of renal activity, is
extremely important to therapeutic regimen decisions and
treatment modiﬁcations as well as prognosis. At present,
activity of SLE is assessed based on clinical symptoms
and biochemistry parameters such as autoantibody (e.g.,
anti-dsDNA) and serum complement. However, current
biomarkers are not speciﬁc for evaluating renal activity.
Renal biopsy has been the gold standard for assessment of
kidney damage and disease activity, but its invasive feature
has restricted its use.
Recently there has been a surge of interest in deﬁning
novel LN biomarkers to evaluate disease activity [1, 2].
Over the last few years, evidences showed that tumor
necrosis factor-like weak inducer of apoptosis (TWEAK) was
expressed in a high level in the kidney of LN animal model.
Patients of LN in active stage had higher urinary TWEAK
level [3]. Researchers presumed that urinary TWEAK level
may reﬂect LN activity. This study approached to the
relationship between urinary TWEAK level and the activity
of LN in the Asian patients in China.
2. Patients andMethods
2.1. Patients. Forty-six cases of patients with LN (12 of
nonactive LN and 34 of active LN) were selected from
patients hospitalized in the Second Xiangya Hospital from
October 2008 to March 2009. Of those 34 cases have routine
renal biopsy. The patients aged 14 ∼ 53 years with a mean
duration of disease for 10.47±4.12 months. Every case meets
atleast4itemsofSLEdiagnosticcriteriarevisedbyAmerican2 Journal of Biomedicine and Biotechnology
RheumatismAssociationin1982.Allthepatientsreceivedno
treatment of immunosuppressive agent such as methylpred-
nisolone (MP), cyclophosphamide (CTX), mycophenolate
(MMF), ciclosporin A (CsA), or tacrolimus (FK506) for 3
months prior to the diagnoses of LN by renal biopsy. Occa-
sionaluseofhydroprednisoneinsomepatientswassubjected
to short time and low doses (<30mg/d). Biopsy specimens
were ﬁxed, sectioning and staining (including HE, PAS,
PASM, and Masson), then observed under light microscopy.
10mL urina sanguinis from each patient was centrifuged.
Then clear supernatant liquid was used for TWEAK and
MCP-1 detection.
2.2. SLE Disease Activity Index Assessment. For renal involve-
ment,renalSLEDiseaseActivityIndex(SLEDAI)wasusedto
assess kidney disease activity. The score consists of the four
kidney-related parameters: hematuria, pyuria, proteinuria,
and urinary casts. Scores for the renal SLEDAI can range
from 0 (inactive renal disease) to a maximum of 16. A
SLEDAI score of 4 was taken as an indicator of active lupus
nephritis.
According to the 2000 SLEDAI scores [4],patients were
divided into two groups: nonactive group and active group.
Nonactive group: 12 cases (3 males and 9 females), LN
duration of 14.06 ± 4.55 months; active group: 34 cases (1
male and 33 females), LN duration of 8.44 ±2.13 months.
Renal biopsy specimens from LN patients were classiﬁed
accordingtotheWorldHealthOrganization(WHO)criteria:
minimal changes (class I), mesangial alterations (class II),
focal proliferative (class III), diﬀuse proliferative (class IV),
and membranous (class V) glomerulonephritis.
2.3. Lupus Nephritis Activity Index and Chronicity Index. We
made semiquantitative score for each renal biopsy specimen
according to 2000 Hill’s Biopsy Index scoring criteria for
lupus nephritis [5]. Activity Index (AI) and Chronicity Index
(CI) were calculated. Activity Index contained Glomerular
Activity Index (GAI) and Tubulointerstitial Activity Index
(TIAI).
(1) Components of Glomerular Activity Index: (1)
glomerular proliferation; (2) polymorphonuclear
leukocytes; (3) karyorrhexis/Fibrinoid necrosis; (4)
cellularcrescents;(5)hyalinedeposits;(6)glomerular
monocytes.
(2) Components of Tubulointerstitial Activity Index: (1)
tubular cell pyknosis; (2) tubular nuclear “activa-
tion”; (3) tubular cell necrosis; (4) tubular cell
ﬂattening; (5) macrophages in tubular lumens; (6)
epithelial cells in tubular lumens; (7) interstitial
inﬂammation.
(3) Activity Index: AI = GAI+TIAI.
(4) Components of Chronicity Index: (1) glomeruloscle-
rosis; (2) glomerular scar; (3) ﬁbrous crescentic; (4)
tubular atrophy; (5) interstitial ﬁbrosis.
2.4. The Detections of Urinary TWEAK and Urinary MCP-
1L e v e l s .Urinary TWEAK levels and urinary MCP-1 levels
were measured by human TWEAK ELISA kits and human
MCP-1 ELISA kits from Xin Bo Sheng Bio-Technology Co.,
Ltd. Shenzhen, China. We measured absorbance A values by
Microplate reader at 450nm wavelength and then calculated
urinaryTWEAKconcentrationsandurinaryMCP-1concen-
trations according to the standard curve. Urinary TWEAK
levels and urinary MCP-1 levels were normalized to urinary
creatinine concentrations measured in the same spot urine,
expressed as pg/mg creatinine.
2.5. Statistical Analysis. SPSS 13.0 statistical package was
used for data analysis. Measurement data consistent with
normal distribution was expressed as χ ± S. LSD-t test
was used for comparing two groups. Association among
categorical variables was measured by Pearson’s Chi-squared
test. Spearman’s analysis was used for correlations between
quantitative data and semiquantitative data or between two
semiquantitative data. P-value < 0.05 was considered statis-
tically diﬀerent and P-value < 0.01 as statistically significant.
3. Results
3.1. Clinical and Laboratory Findings of Lupus Nephritis
Patients. SLE patients (n = 46) were recruited into two
groups: SLE patients with active lupus nephritis (active
group) and those patients with inactive or nonrenal involve-
ment (nonactive group). Statistically, signiﬁcant diﬀerences
were found between both groups in the following vari-
ables: red blood cell count in urine (/HP), 24h urinary
proteins (g/24h), serum BUN (mmol/L), serum creatinine
level (μmol/L), C3 (mmol/L), and C4 (mmol/L). Detailed
comparisons between both groups are presented in Table 1.
3.2. Features of the Histopathology of Active Lupus Nephritis.
The pathological changes of active lupus nephritis contain
glomerular mesangial cells proliferation, cellular crescents,
thickening of capillary walls, karyorrhexis, hyaline thrombi,
and interstitial inﬂammatory inﬁltration (Figure 1).
3.3. The Relationship between TWEAK and LN Activity. To
determine whether TWEAK correlates with LN activity, we
compared urinary TWEAK levels of LN active group with
nonactivegroup.UrinaryMCP-1levelswereusedforpositive
control. As presented in Figure 2, urinary TWEAK levels
of LN active group were signiﬁcantly higher than those
of nonactive group (10.29 ± 1.81pg/mgCr versus 2.14 ±
0.30pg/mgCr, P<0.01). Urinary MCP-1 levels (uMCP-
1) of LN active group were also signiﬁcantly higher than
those of nonactive group (103.60 ± 15.79pg/mgCr versus
20.19 ±2.93pg/mgCr, P<0.01).
3.4. The Relationship between uTWEAK and LN Renal Biopsy
Index. The urinary TWEAK levels of patients with LN had
signiﬁcantly positive correlation (r = 0.825, P<0.01)
with Active Index (AI) (P<0.01), including Glomerular
Activity Index (GAI) (rGAI = 0.745, rTIAI = 0.751) and those
with Tubulointerstitial Activity Index (TIAI), but had noJournal of Biomedicine and Biotechnology 3
Table 1: Comparison between active group and nonactive group in terms of important clinical and laboratory ﬁndings.
Active Group (n = 34)
Mean ±SD
Nonactive Group (n = 12)
Mean ±SD
Male/female ratio 1/33 3/9
Disease duration of SLE (month) 12.71 ±3.39 17.99 ±6.46
Disease duration of LN (month) 8.44 ±2.13 14.06 ±4.55
Red blood cell count in urine (/HP) 6.36 ±0.67 1.88 ±0.61
24-h urinary proteins (g/24hr) 3396 ±1107 1166 ±408
Serum BUN (mmol/L) 10.13 ±1.02 7.84 ±2.11
Serum Cr (μmol/L) 113.50 ±9.23 92.36 ±19.09
Serum C3 (mmol/L) 0.46 ±0.04 0.58 ±0.07
Serum C4 (mmol/L) 0.10 ±0.01 0.14 ±0.02
SLE: systemic lupus erythematosus; LN: lupus nephritis; BUN: blood urea nitrogen; Cr: creatinine; C3: complement3; C4: complement4.
(a) (b)
(c) (d)
(e) (f)
Figure 1: Features of the histopathology of active lupus nephritis. (a) Glomerular mesangial cells proliferation accompanied with cellular
crescents (arrow showed). (HE staining, ×200). (b) Subepithelial immune deposits to form a “platinum ear” (arrow showed). (PASM
staining, ×200). (c) Immune deposits in basement membrane. The “spikes bristle” can be observed in basement membrane (arrow showed).
(PASMstaining, ×1000). (d)Renal tubularepithelial cells shedaccompanied withinterstitialinﬂammatoryinﬁltration(arrowshowed).(HE
staining, ×400). (e) Normal glomerulus without mesangial cells proliferation. (PAS staining, ×200). (f) Normal glomerulus without thick
basement membrane. (PASM staining, ×1000).4 Journal of Biomedicine and Biotechnology
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Figure 2: uTWEAK and uMCP-1 correlate with LN activity. A comparison of uTWEAK and uMCP-1 between 34 cases and 12 nonactive
cases.PatientswithactiverenaldiseasehadsigniﬁcantlyhigherurinaryTWEAKlevelsandhigherurinaryMCP-1levels.Barsindicatemedian
values.
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Figure 3: uTWEAK levels correlated with LN renal biopsy index. uTWEAK levels of 34 patients with LN who had routine renal biopsies
showed positive correlations with Active Index (AI) (r = 0.825, P<0.01), Glomerular Activity Index (GAI) (r = 0.745, P<0.01), and
Tubulointerstitial Activity Index (TIAI) (r = 0.751, P<0.01). uTWEAK levels had no correlation with Chronicity Index (P>0.05).Journal of Biomedicine and Biotechnology 5
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Figure 4: uMCP-1 levels correlated with LN renal biopsy index. A positive correlation (r = 0.800, P<0.01) between Active Index (AI)
and uMCP-1 levels had been found from data of 34 patients with LN who had routine renal biopsies. And the analysis of urinary TWEAK
levels with Glomerular Activity Index (GAI) and those with Tubulointerstitial Activity Index (TIAI) both yield positive (rGAI = 0.804,
rTIAI = 0.769), signiﬁcant (P<0.01) correlations.
signiﬁcant correlation (P>0.05) with Chronicity Index (CI)
(Figure 3).
3.5. The Relationship between Monocyte Chemoattractant
Protein-1 (MCP-1) and LN Activity. Monocyte chemoattrac-
tant protein-1 (MCP-1) has been presumed a biomarker to
monitor LN activity, proved by evidences of biochemistry
and immunology. However, MCP-1 was not reported to pre-
dictrenalhistopathology.Thisstudyanalyzedthecorrelation
between urinary MCP-1 levels and LN renal biopsy index.
ResultsshowedthattheurinaryMCP-1levelsofpatientswith
LN had signiﬁcantly positive correlation (r = 0.800, P<
0.01) with Active Index (AI), including Glomerular Activity
Index (GAI), and those with Tubulointerstitial Activity
Index (TIAI) (rGAI = 0.804, rTIAI = 0.769) but had no
signiﬁcant correlation (P>0.05) with Chronicity Index (CI)
(Figure 4).
3.6. The Relationship between Urinary TWEAK Levels and
Urinary MCP-1 Levels. Relationship of urinary TWEAK
levels with urinary MCP-1 levels was also analyzed. Our
analysis showed that the urinary TWEAK levels in active
group had signiﬁcantly positive correlation (r = 0.809, P<
0.01) with urinary MCP-1 levels, while nonactive group’s
urinary TWEAK levels had no correlation with the urinary
levels of MCP-1 (P>0.05) (Figure 5).
4. Discussion
LN is one of the most common complications of SLE.
In recent years, several studies have found that a disorder
of the regulation of apoptosis is an important factor in
SLE progress, such as TWEAK [6]. TWEAK combined
with its receptor Fn14 could activate Iκ-B kinase (IKK),
resulting in the degradation and activation of Iκ-B. Iκ-B6 Journal of Biomedicine and Biotechnology
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Figure 5: uTWEAK correlated with uMCP-1. Urinary TWEAK levels of 34 patient with active LN had signiﬁcantly positive correlation with
urinary MCP-1 levels, r = 0.809, P<0.01. In disease nonactive group, 12 patients’ urinary TWEAK levels had no correlation with their
urinary MCP-1 levels.
transferred to cell nucleus and increased MCP-1, RANTES,
and IL-6 expression, causing inﬂammatory cell inﬁltration.
Researches also reported that TWEAK/Fn14 induced apop-
tosis of glomerular mesangial cells and tubular epithelial
cells with induction of proinﬂammatory cytokines, thereby
causing glomerular and tubular injury, which might play an
important role in the pathogenesis of lupus nephritis [7, 8].
In this study, we analyzed the relationship between TWEAK
and the renal activity of lupus in order to prove TWEAK as a
marker of lupus nephritis.
Previous studies have shown that serum TWEAK levels
are signiﬁcantly lower in SLE patients than in healthy
individuals [9, 10]. A cross-sectional study by Gladman et al.
[4] in the Ohio SLE Research Center and the Albers Albert
Einstein Medical College showed that patients with lupus
nephritis had signiﬁcantly higher urinary TWEAK levels
than those without kidney injury, and the patients in active
stage of lupus, with kidney injury or not, had higher urinary
TWEAK levels than those in nonactive stage, indicating that
anelevatedlevelofurinaryTWEAKmaysuggestactivelupus
nephritis. In our study, active LN patients had signiﬁcantly
higher urinary TWEAK levels, compared to those in chronic,
stable condition. This result was similar to the ﬁndings of
Schwartz et al. [11] focused on the cases in USA. And our
study provides a supporting result to the conclusion by
Schwartz et al. in Chinese patients, indicating that TWEAK
also played an important role in the active lupus nephritis in
Asian cases.
In this study, the correlation between MCP-1 and LN
activity has been conﬁrmed by histopathological evidence.
Results also showed that urinary TWEAK levels had signif-
icantly correlated with LN renal pathology AI containing
GAI and TIAI. However, no relationship was found between
urinary TWEAK levels and CI. This indicates that urinary
TWEAK levels could reﬂect the level of activity in LN
patients. In addition, the expression of TWEAK is relevant
to glomerular lesions and tubulointerstitial lesions. The
elevation of urinary TWEAK level may be related to the
increased expression of TWEAK in kidney. However, it is
still uncertain whether kidney is the only organ expressing
TWEAK, which is needed to be conﬁrmed in the future. We
also found that urinary TWEAK levels have no diﬀerence
between Class II, III, and IV of LN among 31 patients (Result
isnotshowedinthisarticle),indicatingthaturinaryTWEAK
detection cannot replace renal biopsy entirely in diagnostic
process.
MCP-1 was proved to be a biomarker of lupus nephritis
disease activity [12, 13]. In vivo, urinary MCP-1 has
positive correlation with the increase in urine n-acetyl-β-d-
glucosaminidase (NAG) and urine protein in 24h [14]. A
signiﬁcantly positive correlation between MCP-1 and AI has
been showed in our study (Figure 4). In addition, urinary
TWEAK levels have signiﬁcantly positive correlation with
active LN (r = 0.809, P<0.01) and urinary levels of MCP-
1, pointing to the potential of urinary TWEAK as a disease-
monitoring biomarker. Activated T lymphocytes expressed
TWEAK, resulting in increasing apoptosis of mononuclear
cells. The injured mononuclear cells released nuclear self-
antigens by increasing MCP-1 expression, and the clearance
of apoptotic debris reduced relatively, which might be one
of the mechanisms for the development of lupus. Researches
indicated that TWEAK combined with Fn14 induced MCP-1
in renal tubular epithelial cells, causing RelA subunit of NF-
κB transferring from cytoplasm to nucleus, leading to the
activation of target gene which encodes MCP-1 [6, 15, 16].
These results proved that TWEAK is one of the upstream
regulatory factors of MCP-1 in inﬂammatory process.
In conclusion, urinary TWEAK levels of patients with
active LN signiﬁcantly positively correlated with urinary
levels of MCP-1, indicating the potential disease-monitoring
biomarker of urinary TWEAK.
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